The international phase III trial IMspire170 found that atezolizumab in combination with cobimetinib (a MEK inhibitor) did not improve PSF in patients with advanced melanoma compared to pembrolizumab monotherapy, with 5.5 and 5.7 months, respectively (23). This evidence concerns the gene MAP2K7 and melanoma.